Australian medical marijuana & recreational cannabis news covering culture, activism, law, products, history, business, event coverage & more.

Zelda Therapeutics uncovers cannabis anti-cancer effect

Zelda Therapeutics announced positive results from its ongoing research into the use of medicinal cannabis, seeing it's share price skyrocket.
4.89K

ASX Listed Company, Zelda Therapeutics Ltd (ASX: ZLD) share price has jumped as much as 62% on Friday after the biotechnology company announced positive results from its ongoing pre-clinical research into the use of medicinal cannabis.

This morning Zelda announced positive results from its ongoing pre-clinical research into the use of cannabinoids as anti-cancer agents.

According to the release, the latest results from a series of in vitro studies have confirmed that both THC-rich and CBD-rich oils have had a statistically significant anti-cancer effect across a range of different breast cancer cell lines.

Management believes these results demonstrate the potential for cannabinoid-based therapies to be therapeutically beneficial for a number of breast cancer types which include hormone receptor positive, HER2+, and triple negative cancer types.

Zelda expects to release further data in the next few months related to additional in vitro and in vivo studies.

Read the full article on fool.com.au

What do you think about Zelda Therapeutics positive results from its ongoing research into the anti-cancer effects of medicinal cannabis?

Whilst it’s pleasing to record significant anti-cancer effects across a range of different breast cancer cell lines, it is far too early to say how much of an impact medicinal marijuana will have on some of the world’s most debilitating diseases and health issues.

Regardless of the final outcome of Zelda Therapeutics’ studies into the anti-cancer effects of THC-rich and CBD-rich oils , the discovery of more and more health benefits and medical applications available to medical cannabis consumers, makes it an exciting time to be alive, to potentially witness first-hand a shift towards an alternative type of medicine.